THCV

The main cannabinoid receptor in the brain, responsible for THC’s intoxicating effects. Human-receptor research found THCV and Delta-9-THC to have approximately 1.0x the same CB1 binding affinity, showing that THCV can occupy the receptor about as effectively as Delta-9-THC.

Unlike Delta-9-THC, THCV generally blocks CB1 signalling rather than activating it. Functional research found little to no CB1 agonist activity and showed that THCV can give activation like other CB1 agonists. However, other assays found THCV could activate specific pathways such as ERK and β-arrestin signalling, indicating that its CB1 behaviour is pathway-dependent.

This CB1 antagonism can reduce some Delta-9-THC effects in humans. In a controlled study, THCV alone was subjectively indistinguishable from placebo, while 9 of 10 participants experienced subsequent Delta-9-THC as less intense. THCV also reduced the THC-related increase in heart rate and prevented impairment in one memory measure, although some other effects were unchanged or increased.

The main cannabinoid receptor in the immune system, involved in regulating immune cell activity and inflammatory responses. Direct human-receptor research found that THCV has approximately 1.1x stronger CB2 binding affinity than Delta-9-THC, meaning their binding strength is very similar.

THCV acts as a partial CB2 agonist, although its functional behaviour varies between experimental systems. Earlier research has also observed antagonist-like behaviour under different testing conditions, suggesting that its effect can depend on how CB2 signalling is measured.

CB2 activation may reduce inflammatory signalling and contribute to pain-reducing effects. Animal research supports CB2 involvement in some THCV effects, but specific CB2 effects have not yet been confirmed in humans.

The 5-HT1A serotonin receptor helps regulate mood, stress, cognition and emotional processing. THCV does not strongly activate this receptor by itself, but instead appears to enhance its response to other agonists. In rat brain tissue, 100 nM THCV increased the potency of the 5-HT1A agonist 8-OH-DPAT by approximately 240.9x, without increasing its maximum effect. Experiments using human 5-HT1A receptors also confirmed enhanced receptor activation, although there THCV mainly increased the maximum response rather than potency. This is classifies THCV acting as a positive allosteric modulator of 5-HT1A signalling.

Animal research suggests this mechanism can produce meaningful neurological effects. In rat models, THCV reduced several schizophrenia-like behavioural and cognitive changes, and blocking 5-HT1A prevented or reduced some of these effects. This confirms a direct contribution from THCV to enhanced 5-HT1A signalling, although specific effects have not been confirmed in humans.

TRP channels are ion channels involved in pain, temperature and sensory signalling. THCV directly affects several of these channels, including TRPV1, TRPV2, TRPV3 and TRPV4, while it inhibits TRPM8.

THCV activates and then desensitizes TRPV1, a channel involved in heat and pain signalling. Initial activation can increase sensory signalling, while the later desensitization makes the channel less responsive and could therefore contribute to reduced pain signalling.

THCV also activates and desensitizes TRPV2. This initially increases calcium entry and cellular signalling, while subsequent desensitization reduces the channel’s responsiveness and could contribute to pain-reducing and sensory effects.

At TRPV3, THCV acts as an activator. This channel is involved in warmth detection and sensory signalling, so activation could increase warmth-related signalling. Repeated activation can also make the channel less responsive over time.

THCV activates TRPV4, which is involved in temperature, pressure and pain-related signalling. This increases calcium signalling inside cells and could enhance certain sensory responses.

THCV inhibits TRPM8, a channel involved in sensing cold temperatures and cooling sensations. This reduces TRPM8 activity and could decrease cold-sensitive signalling and sensitivity to cold-related discomfort or pain.

These TRP interactions are established in laboratory research, but their contribution to THCV’s specific effects in humans remains uncertain.

GPR55 is a receptor involved in pain, metabolism and cellular signalling. THCV appears to have a mixed modulatory effect at GPR55 rather than behaving as a simple agonist or antagonist.

THCV can weakly activate GPR55 on its own, but it can also reduce stronger GPR55 signalling triggered by LPI (the receptor’s natural agonist). This suggests that THCV may regulate GPR55 activity by producing mild activation while limiting stronger stimulation from other molecules.

Through this mechanism, THCV could potentially influence pain signalling and metabolic processes such as appetite regulation. However, the contribution of GPR55 to THCV’s effects in humans has not yet been established.

Human liver-cell research confirms that Delta-9-THCV is extensively metabolized, with THCV-COOH identified as a major breakdown product. This metabolite has also been detected in human urine after cannabis exposure.

Formation of 11-OH-THCV as an intermediate is biologically plausible and would resemble the conversion of Delta-9-THC into 11-OH-THC. However, 11-OH-THCV has not yet been sufficiently confirmed or characterized in humans, and whether it remains pharmacologically active or psychoactive is unknown.